Polycystic ovarian syndrome (PCOS) is the most common endocrine pathology in females of reproductive age worldwide. Insulin resistance has been associated highly with PCOS. The complications of PCOS may vary from seeking fertility, regulation of menstrual disturbances, relief from hyperandrogenic symptoms, (acne, hirsutism, or androgenic alopecia) or heightened risk of developing obesity, metabolic disorder, impaired glucose tolerance (IGT), type-2 diabetes mellitus, and cardiovascular disease. It is recommended to start metformin in PCOS patients with T2DM or IGT who fail lifestyle modifications. On this & more, renowned Endocrinologist & former president of the Endocrine Society of India, Dr. Rakesh Sahay joins us LIVE in this pivotal discussion on Medflix!

Polycystic Ovarian Syndrome :  What Every Physician Needs To Know

Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. An expert group convened by the ADA proposed “remission” as the most appropriate descriptive term for describing this process, and HbA1c <6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy as the usual diagnostic criterion. New classes of drugs, the glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter inhibitors, can sometimes attain excellent glycemic control with little tendency to cause hypoglycemia. A diagnosis of remission can only be made after all glucose-lowering agents have been withheld for an interval that is sufficient both to allow waning of the drug’s effects and to assess the effect of the absence of drugs on HbA1c values. Let us hear from Prof. Dr. Rakesh Sahay, current President of the Endocrine Society of India, all there is to know about the criterion for diagnosing Remission in T2DM.

Remission in T2DM

Insulin therapy has greater potential to reduce hyperglycemia than other therapies; however, there is often a significant delay in insulin initiation and intensification. Current treatment guidelines recognize the important role of Insulin Therapy both early on and throughout the progression of type 2 diabetes. In this discussion, Dr Rakesh Sahay, President - Endocrine Society of India, presents to us the scientific rationale about the need, goals, timing, initiation and titration of insulin therapy in patients with Type 2 DM. Join in LIVE to comprehend how to individualize Insulin Therapy in T2DM.

How to individualize Insulin Therapy in T2DM?

Hemoglobin A1c (A1c), which was first used clinically in the 1970s, is now the gold standard for assessing glycemic control in diabetic patients. The American Diabetes Association expanded the use of the A1c test by including it as a diagnostic standard for diabetes in 2010. Since hemoglobin A1c plays a crucial part in both diagnosis and therapy, it's critical to identify clinical situations and influencing variables that lead to inaccurate results. Let's understand Pitfalls, Caveats and, Variations of HbA1c interpretation.

HbA1c Interpretation: Pitfalls, Caveats, Variations

President, Endocrine Society of India | Professor & HOD, Dept. of Endocrinology | Osmania Medical College & Hospital, Hyderabad.

Dr. Rakesh Sahay

4

3.8K

59.1K

4.5

Sessions Taken

0

0

826

4.6

1.2K

4.6

1.1K

4.4